Heart Hormones Protect Against Obesity and Insulin Resistance
Elevated levels of natriuretic peptides in adipose tissue protect against effects of high-fat diet
25-Aug-2017 12:00 AM EDT
Newswise — Orlando, Fla., August 25, 2017 – Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) in Lake Nona, Florida have shown that enhanced natriuretic peptide (NP) signaling in adipose tissue protects against obesity and insulin resistance. The findings suggest that boosting levels of NPs in adipose tissue may be an important avenue to explore for combating metabolic disease. The study was published in Science Signaling.
“For years we have known that NPs control blood pressure and can promote the conversion of energy-storing ‘bad’ white fat into energy-burning ‘good’ brown fat, says Sheila Collins, Ph.D., professor in the Integrative Metabolism Program at SBP Lake Nona and senior author on the paper. “What we discovered in this study is the important role for NPs in managing metabolism and resisting the deleterious effects of a high-fat diet.”
Made in the heart, atrial and B-type natriuretic peptides (NPs) are hormones that were originally discovered to modulate salt and water to control blood pressure. These peptides transmit their signals through natriuretic peptide receptor A (NPRA). Meanwhile, natriuretic peptide receptor C (NPRC) removes NPs from circulation.
“We wanted to explore the difference between elevated levels of NPs in adipose tissue compared to skeletal muscle tissue. Understanding the distinctions can help us devise strategies and treatments to potentially improve metabolic health—including obesity and insulin resistance,” says Collins.
To study this interplay, the researchers studied mice with NPRC receptors selectively knocked out in either adipose or skeletal muscle tissue. While deleting NPRC in muscle provided no protection from a high-fat diet, eliminating the receptor in adipose tissue improved insulin sensitivity, prevented obesity and increased sugar uptake in metabolism-boosting brown fat. In addition, the adipose knockout mice showed higher energy expenditure and less inflammation.
“Usually when you feed mice high-fat diets they get fatty liver,” says Collins. “In mice without NRPCs in adipose tissue the liver was completely clean and completely devoid of stored lipids, which I’m sure contributes to their improved overall metabolic performance.”
These findings dovetail with clinical research that has shown naturally lean people tend to have higher NP concentrations in their blood. By contrast, NP clearance tends to rise in fat tissue, removing these peptides from the blood and making it more difficult for effective NP signaling to happen.
Around a third of adults in the U.S. are obese, increasing their risk for type 2 diabetes, metabolic syndrome, fatty liver disease and other conditions. With these results, scientists can begin exploring NPs as therapeutic targets. This will require intense investigation, as any effective treatment must avoid adverse effects on blood pressure. While this study increased the NP signal by knocking out NPRCs, another approach might be to focus on NPRAs.
“I think this further reinforces that it is really the adipose tissue that’s an important site to take advantage of this signaling mechanism,” says Collins. “We could make versions of these peptides that bind to the signaling form (NPRA) of the receptor better than the clearance form, or we could make agents that are only are recognized by the clearance receptor, thus providing better access of the NPs to NPRA.
“However, before any therapy can move forward, more work must be done to better understand these protective mechanisms and unwind the complex interrelationships between NPs, white fat, brown fat and possibly other players,” adds Collins.
This work was supported by the NIH (R01 DK103056).
Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children’s diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.